Dose Cefpirome 500 mg IV every 12 hours for this patient with moderate renal impairment
For an 82-year-old male with AKI (creatinine 1.5 mg/dL, eGFR 44 mL/min/1.73 m²) and UTI, reduce cefpirome to 500 mg IV every 12 hours. The sulbactam component (if combined) should be dosed at 250 mg every 12 hours, maintaining the 2:1 ratio.
Rationale for Dose Adjustment
Your patient has moderate renal impairment (eGFR 44 mL/min/1.73 m²), which falls into the CrCl 30-60 mL/min range. Cefpirome is eliminated approximately 80% unchanged in the urine, primarily by glomerular filtration 1. The drug's clearance correlates strongly with creatinine clearance (correlation coefficient 0.747), making renal function the primary determinant of dosing 2.
Key pharmacokinetic changes in renal impairment:
- In patients with CrCl 40-80 mL/min, the elimination half-life extends from 2.36 hours to 3.45 hours 3
- The AUC increases from 96.7 to 172.0 μg·h/mL in this renal function range 3
- Mean cefpirome clearance drops to 42.7 mL/min when CrCl is 18-50 mL/min, compared to 107.6 mL/min when CrCl exceeds 80 mL/min 2
Specific Dosing Algorithm
For eGFR 30-60 mL/min (your patient at 44 mL/min):
- Cefpirome: 500 mg IV every 12 hours
- Sulbactam: 250 mg IV every 12 hours (if using combination)
- Infusion time: 30 minutes
If eGFR drops below 30 mL/min:
- Reduce to 500 mg every 24 hours
If requiring hemodialysis:
- Give 500 mg after each dialysis session (hemodialysis removes 48% of the drug) 4
Treatment Duration and Monitoring
For complicated UTI in an elderly male (which this is, given his age and AKI), treat for 7-14 days 5. The longer duration (14 days) is appropriate when prostatitis cannot be excluded in males 5.
Critical monitoring points:
- Reassess renal function every 48-72 hours during AKI
- Watch for neurotoxicity if renal function worsens further (cephalosporins accumulate and can cause seizures)
- Consider switching to oral therapy after 48 hours of clinical improvement if patient is hemodynamically stable 5
Important Caveats
Avoid early dose reduction pitfalls: While dose reduction is necessary for safety, recent evidence suggests that overly aggressive early reductions in the first 48 hours may lead to underdosing, especially if AKI is transient 6. However, at eGFR 44 mL/min with creatinine 1.5, this represents established moderate impairment requiring adjustment from the start.
Serum creatinine limitations: In elderly patients, more than half with CrCl <50 mL/min have serum creatinine within the "normal" range of 70-150 μmol/L 2. Your patient's creatinine of 1.5 mg/dL (approximately 133 μmol/L) may underestimate the degree of renal impairment given his age and likely reduced muscle mass.
Alternative considerations: If this is a complicated UTI with multidrug-resistant organisms, the guidelines recommend broader agents like ceftazidime-avibactam 2.5 g IV every 8 hours (adjusted for renal function) or meropenem-vaborbactam 7. However, for empiric therapy of standard complicated UTI, the adjusted cefpirome-sulbactam regimen is appropriate 7.